Tibra Equities Europe’s Vertex Pharmaceuticals VRTX Stock Holding History

Tibra Equities Europe’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-10,650	Closed	-$2.52M	–	126
2020 Q4	$2.52M	Buy	+10,650	New	+$2.44M	0.26%	48
2019 Q1	–	Sell	-11,000	Closed	-$1.82M	–	474
2018 Q4	$1.82M	Buy	+11,000	New	+$1.91M	0.3%	61

Other funds holding VRTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Tibra Equities Europe's VRTX Position: Q1 2021 in Review

Tibra Equities Europe sold out of Vertex Pharmaceuticals (VRTX) in Q1 2021, closing a stake of 10,650 shares — an estimated $2.52M sold.

Tibra Equities Europe first reported a position in VRTX in Q4 2018 and held it in 2 quarters. The position peaked at $2.52M in Q4 2020. 999 funds tracked by Wall St. Rank hold VRTX as of Q1 2021.

Tibra Equities Europe reported no remaining Vertex Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
Tibra Equities Europe sold 10,650 Vertex Pharmaceuticals shares in Q1 2021, an estimated $2.52M.
Tibra Equities Europe first reported a position in Vertex Pharmaceuticals in Q4 2018 and held it in 2 quarters.
Tibra Equities Europe's Vertex Pharmaceuticals position peaked at $2.52M in Q4 2020.
999 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2021.

Based on Tibra Equities Europe's 13F filing for Q1 2021, filed 17 May 2021.